Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS.

Cell. 2011 Sep 16;146(6):904-17. doi: 10.1016/j.cell.2011.08.017. Epub 2011 Sep 1.

2.

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR.

Nature. 2011 Aug 3;478(7370):524-8. doi: 10.1038/nature10334.

3.

Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system.

Heneweer C, Holland JP, Divilov V, Carlin S, Lewis JS.

J Nucl Med. 2011 Apr;52(4):625-633. doi: 10.2967/jnumed.110.083998. Epub 2011 Mar 18.

4.

Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques.

Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ.

J Nucl Med. 2010 Dec;51(12):1937-49. doi: 10.2967/jnumed.110.076232. Epub 2010 Nov 15. Review.

5.

Selective inhibition of BET bromodomains.

Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE.

Nature. 2010 Dec 23;468(7327):1067-73. doi: 10.1038/nature09504. Epub 2010 Sep 24.

6.

89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS.

J Nucl Med. 2010 Aug;51(8):1293-300. doi: 10.2967/jnumed.110.076174. Epub 2010 Jul 21.

7.

Unconventional nuclides for radiopharmaceuticals.

Holland JP, Williamson MJ, Lewis JS.

Mol Imaging. 2010 Feb;9(1):1-20. Review.

8.

Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.

Holland JP, Caldas-Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, Chiosis G, Lewis JS.

PLoS One. 2010 Jan 25;5(1):e8859. doi: 10.1371/journal.pone.0008859.

9.

Standardized methods for the production of high specific-activity zirconium-89.

Holland JP, Sheh Y, Lewis JS.

Nucl Med Biol. 2009 Oct;36(7):729-39. doi: 10.1016/j.nucmedbio.2009.05.007. Epub 2009 Jul 29.

10.

Molecular scintigraphic imaging using 99mTc-transferrin is useful for early detection of synovial inflammation of collagen-induced arthritis mouse.

Lee SI, Kim EM, Kim SL, Lee CM, Jang KY, Yun HJ, Yoo WH, Sohn MH, Jeong HJ.

Rheumatol Int. 2008 Dec;29(2):153-7. doi: 10.1007/s00296-008-0655-z. Epub 2008 Aug 12.

PMID:
18696076
11.

Dissecting the role of PtdIns(4,5)P2 in endocytosis and recycling of the transferrin receptor.

Abe N, Inoue T, Galvez T, Klein L, Meyer T.

J Cell Sci. 2008 May 1;121(Pt 9):1488-94. doi: 10.1242/jcs.020792. Epub 2008 Apr 14.

12.
13.

Multimodality registration without a dedicated multimodality scanner.

Beattie BJ, Förster GJ, Govantes R, Le CH, Longo VA, Zanzonico PB, Bidaut L, Blasberg RG, Koutcher JA.

Mol Imaging. 2007 Mar-Apr;6(2):108-20.

PMID:
17445505
14.

Regulation of transferrin recycling kinetics by PtdIns[4,5]P2 availability.

Kim S, Kim H, Chang B, Ahn N, Hwang S, Di Paolo G, Chang S.

FASEB J. 2006 Nov;20(13):2399-401. Epub 2006 Sep 28.

PMID:
17012244
15.

The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.

Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML.

Clin Immunol. 2006 Nov;121(2):144-58. Epub 2006 Aug 10. Review.

PMID:
16904380
16.

Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.

O'Donnell KA, Yu D, Zeller KI, Kim JW, Racke F, Thomas-Tikhonenko A, Dang CV.

Mol Cell Biol. 2006 Mar;26(6):2373-86.

17.

Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.

Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL.

Cancer Res. 2005 Dec 15;65(24):11565-71.

18.

Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG.

Pellegrino D, Bonab AA, Dragotakes SC, Pitman JT, Mariani G, Carter EA.

J Nucl Med. 2005 Sep;46(9):1522-30.

19.

Preparation, biodistribution, and small animal PET of 45Ti-transferrin.

Vavere AL, Welch MJ.

J Nucl Med. 2005 Apr;46(4):683-90.

20.

The transferrin receptor: a potential molecular imaging marker for human cancer.

Högemann-Savellano D, Bos E, Blondet C, Sato F, Abe T, Josephson L, Weissleder R, Gaudet J, Sgroi D, Peters PJ, Basilion JP.

Neoplasia. 2003 Nov-Dec;5(6):495-506.

Supplemental Content

Support Center